Skip to main content
. Author manuscript; available in PMC: 2023 Sep 8.
Published in final edited form as: Sci Transl Med. 2023 Feb 8;15(682):eabn5649. doi: 10.1126/scitranslmed.abn5649

Fig. 1. Intratumoral D2C7 and αCD40 combination elicit robust antitumor immunity in orthotopic glioma models.

Fig. 1.

(A) Survival of C57BL/6J mice implanted with CT-VIII (N=10/group) cells and treated with Ctrl, D2C7, αCD40, or D+C as indicated. (B) Treated mice from A that experienced complete tumor regression for >75-d, were rechallenged with the CT-2A tumor cells. Tumor naïve mice (n=7) served as controls. (C) Survival of mice implanted with GL-VIII (n=5/group) cells and treated with Ctrl, D2C7, αCD40, or D+C as indicated. (D) Treated mice from C that experienced complete tumor regression for >83-d, were rechallenged with the GL261 tumor cells. Tumor naïve mice (n=5) served as controls. (E-H and J-M) Representative images of H&E stained tumor sections from CT-VIII (E-H) brains (n=6–7/group, harvested 6–7-d post-therapy) and GL-VIII (J-M) brains (n=3/group, harvested 6-d post-therapy), treated with control (E, J), D2C7 (F, K), αCD40 (G, L), or D+C (H, M). Scale bar: 600 μm. (I and N) Percentage compositions of tumor cells of entire CT-VIII (I) and GL-VIII (N) tumor section cohorts from E-H and J-M are presented. Data are mean ± SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. BLI, Bioluminescence imaging.